

CIN: L63090TN2000PLC046338

November 18, 2015

TAKE/BSE/2015-16

TAKE/NSE/2015-16

The Manager
Dept. of Corporate Services-Listing
Bombay Stock Exchange Limited,
P. J. Towers, Dalal Street,
Mumbai - 400001

The Manager-Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex, Bandra (East),
Mumbai - 400051

Dear Sir,

Sub: Press Release

We are pleased to enclose a press release for your reference and record.

Kindly note the same and do the needful.

Thanking you,

Yours faithfully,
For TAKE Solutions Limited



Karthic P R
Asst. Company Secretary



TAKE to add new vistas supporting the development of Biosimilars, Regenerative Medicine and Diagnostic Imaging Agents

-Acquires Ecron Acunova in an INR 115 Crore deal-

- Acquisition to broaden addressable market, enhance domain expertise & deliver differentiated value to its customers
- Targets the largely untapped Biosimilars, Regenerative Medicine and Diagnostic Imaging Agents space by increasing its IP assets.

India, Chennai, November 18, 2015: TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE], a leading global domain focused technology company with significant expertise in Life Sciences (LS), today announced that it has entered into definitive agreements to acquire a Life Sciences Services player, Ecron Acunova (EA).

This association will enable TAKE add expertise in the areas of Biosimilars, Regenerative Medicine and Diagnostic imaging agents space which are emerging growth areas. This will help TAKE move the addressable market for its services to 30 bn \$. It will also significantly enhance presence in Europe and Nordic countries.

With the coming together of the two organizations, TAKE will explore new vistas of the dynamic Pharmaceutical, Biotechnology, and Medical Device R&D markets including the areas of Biosimilars, Regenerative Medicine and Diagnostic Imaging Agents. TAKE's enhanced capabilities will enable it to be an integral part of the fast growing Biosimilars space. As an innovation driven organization, TAKE will also now be able to expand its IPs in Risk Based Monitoring and other solutions aimed at bringing safe, effective, and affordable drugs and devices to market.

With this acquisition, TAKE will add audit ready infrastructure in Europe and India, and parts of South Asia to its expanding footprint. The organization will also augment its pool of subject matter experts by 30% and Life Sciences talent by 50%, significantly amplifying its experience, innovation and domain expertise. In addition, the Full Service capability along with expanded infrastructure will allow TAKE to service the mid-market as well.

Mr. Srinivasan H.R., Vice Chairman & Managing Director, TAKE Solutions said, "Globally, there is a growing focus on quality, data, analytics and outcomes in the industry, resulting in increased pharma/biotech R&D spending and funding. This acquisition will enhance our addressable market from 15.9 bn \$ to over 30 bn \$ by 2019, giving us great headroom for growth." He further added, "TAKE & EA's combined attributes will strengthen our position as a fully integrated differentiated Life Sciences services provider to large and small global pharmaceutical companies and thereby broaden the addressable market.

Deal benefits:

- Targeting a market opportunity - USD 30 billion by 2019.
- Targets the largely untapped Biosimilars space
- Life Sciences headcount up by 50%
- Life Sciences Subject Matter Experts up by 30%
- Combined footprint will cover all of North America, portions of South America, Western Europe and Nordic, Central and Eastern Europe, India, South East Asia, MENA and APAC

About TAKE Solutions

TAKE Solutions, is a globally recognized knowledge intensive technology player, delivering comprehensive and niche solutions for enterprises across diverse sectors for over 15 years, with key expertise in Life Sciences (LS) and Supply Chain Management (SCM). In the LS domain, TAKE offers IP-based software and extensive knowledge-based solutions to enable efficient clinical, regulatory, safety and content management. In SCM, TAKE's product suite includes distinct technology with embedded IP that spans enterprise mobility, trading partner collaboration, and material tracking.

TAKE encompasses specialized lines of businesses under distinct brands such as Navitas - a pure play Life Sciences company, TAKE Supply Chain & TAKE MEA - flexible, accessible, mobile Supply Chain software solution providers, APA Engineering - an International Sourcing and Engineering services company, TAKE Innovations - an incubator to facilitate IP Creation and TAKE Enterprise Services Inc. - a specialist provider of technology-driven business solutions and software services.

TAKE's significant recognitions include a patent win from the United States Patent and Trademark Office (USPTO) for its 'Method for Optimizing Clinical Data Standardization', a 'Leader' certification in Drug Safety Services & Life Sciences R&D IT Outsourcing from IDC, recognition as the 'Dream Employer of the Year' at the World HRD Congress and the title of 'Most Admired Brand -IT' from the Asian Customer Engagement Forum. With its global headquarters in Chennai, India, TAKE has a proven track record of delivering world-class solutions to more than 400 customers worldwide, including 9 of the top 10 global Pharma companies. For more information, please visit www.takesolutions.com

About Ecron Acunova

Ecron Acunova is a Life Sciences services company delivering pharmaceutical research services to global clients across South East Asia, Central & Nordic Europe and North America. Along with catering to Big Pharma clients, EA's capabilities lay in delivering highly specialized services to small/medium size biotech and pharma companies in the areas of Pharmacovigilance, Regulatory Affairs, Strategic Consulting, Clinical Data Management and Biostatistics, Medical Writing, Clinical Trials Phases II-IV and Bioavailability & Bioequivalence (BA/BE).

For more information, please visit www.ecronacunova.com

Contacts:

Annapoorna K., TAKE Solutions Ltd., annapoorna@takesolutions.com, Tel: +91 44 2435 7359/60
Murugan G, 20:20 MSL, murugan.g@2020msl.com, Mobile: +91 9841278904